Q-omics provides the consensus-scored SWT1 profile across patient tissues and cancer cell-line models. SWT1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SWT1 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, SWT1 RNA expression shows 20,933 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where SWT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SWT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SWT1 survival associations across molecular data types. SWT1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SWT1 RNA expression–survival associations across cancer types. High SWT1 expression shows unfavorable associations in LIHC, ACC and LGG, but favorable associations in KIRC, UCS and GBM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SWT1 RNA expression.
This table summarizes SWT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SWT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SWT1 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LIHC, BLCA and CHOL. The THCA box plot shows higher SWT1 RNA expression in normal versus tumor tissue (log2 FC = −0.835, t-test p < 0.001).
This table shows molecular features associated with SWT1 in patient tissues and cancer cell lines. In patient samples, SWT1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SWT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
